1. Introduction {#sec1-molecules-21-00672}
===============

Recently, poorly water soluble drugs have received increasing interests in the pharmaceutical industry. According to the Biopharmaceutics Classification System (BCS), drugs are categorized into four classes (class I, II, III, and IV) based on their solubility and membrane permeability \[[@B1-molecules-21-00672]\]. For BCS class II drugs, dissolution is a rate-limiting step to their gastrointestinal absorption and bioavailability. The bioavailability of a class II pharmaceutical compound with adequate cell membrane permeability depends on the dissolution of the compound. This has encouraged the pharmaceutical industry to look for new strategies to enhance the dissolution rate of such drugs in order to improve their bioavailability. When a pharmaceutical compound has high permeability but a water solubility of less than 1 μg/mL, conventional drug formulations may be unacceptable. Thus, the development and selection of suitable formulations are crucial to producing successful products for oral administration of BCS class II drugs.

Orally administered drugs that are rapidly absorbed from the gastrointestinal tract and have a short half-life are quickly eliminated from systemic circulation. This is one of the factors that affect the oral bioavailability of some drugs. Various types of sustained release drug formulations have been suggested to allow the slow release of drugs, resulting in increased residence time in the gastrointestinal tract. However, clinical trials often fail to show evidence of acceptable efficacy.

Currently, several strategies have been suggested for improving the solubility of BCS class II drugs, including crystal modification, particle size reduction, pH modification, amorphization, and lipid-based formulations \[[@B2-molecules-21-00672]\]. Lipid-based formulations have been extensively studied, and have shown various advantages such as the ability to release the drug in a controlled and targeted manner; high and enhanced drug content and stability; favorable biodegradability and biocompatibility; versatility of excipients and formulations; and low risk profile \[[@B3-molecules-21-00672]\]. In particular, nanostructured lipid nanocarriers (NLC) are considered an alternative lipid-based carrier system to liposomal vesicles, emulsions, and solid lipid nanoparticles (SLN). However, they also have some drawbacks that need to be overcome for successful delivery to the target site with controlled release of incorporated drugs. Short gastric retention time (GRT), unpredictable short gastric emptying time (GET), and lipolysis in the upper intestine are responsible for reduced bioavailability of drugs upon oral administration \[[@B4-molecules-21-00672]\]. Surface modification of a drug delivery carrier via introduction of a positive charge is hypothesized to overcome the drawbacks of conventional formulations, improving system stability as well as allowing effective, site-specific drug delivery. In general, positively charged delivery carriers regulate the release rate of drugs depending on biological conditions and enhance drug uptake via electrostatic interactions with sialic acid of mucin in the GI tract \[[@B5-molecules-21-00672],[@B6-molecules-21-00672]\].

In pharmaceutical industry, chitosan is often used as a surface modification agent for various drug delivery systems to improve their performance \[[@B7-molecules-21-00672],[@B8-molecules-21-00672]\]. Chitosan and its derivatives have been extensively studied with respect to their potential to improve the performance of drug carriers by enhancing drug loading, absorption, via specific targeting, controlled and sustained release, among others. In particular, the coating of a drug delivery carrier with cationically modified chitosan derivative was demonstrated to have improved the delivery performance of the cationic primary amino group of chitosan \[[@B9-molecules-21-00672]\]. Based on previous reports, we hypothesized that the impregnation of cationically modified chitosan derivative could improve the dissolution rate of poorly water soluble drugs by coating the surface of conventional NLC formulations. The aim of this study was to improve the solubility of poorly water soluble drugs and investigate the possibility of the application of cationically modified chitosan derivative as a surface modification agent to improve the drug delivery performance of lipid nanocarrier. A model drug, indomethacin was incorporated in NLC formulations to improve its water solubility and bioavailability.

2. Results and Discussion {#sec2-molecules-21-00672}
=========================

2.1. Synthesis and Characterization of HTCC {#sec2dot1-molecules-21-00672}
-------------------------------------------

HTCC synthesis was confirmed by ^1^H-NMR and FT-IR spectra. The ^1^H-NMR spectra of unmodified chitosan and HTCC are shown in [Figure 1](#molecules-21-00672-f001){ref-type="fig"}. A strong resonance at 3.2 ppm was observed in the HTCC spectrum, indicative of a trimethyl group of the quaternary ammonium side chain; however, this was not observed in the chitosan spectrum \[[@B10-molecules-21-00672]\]. The resonances at around 4.8 ppm and 3.1 ppm were attributable to the H-1 and H-2 of glucosamine unit (GlcN), respectively, in both chitosan and HTCC spectra \[[@B11-molecules-21-00672]\]. Furthermore, the resonance at around 4.6 ppm corresponded to the H-1 of the *N*-acetylglucosamine unit (GlcNAc). The resonance at around 2.0 ppm represents three protons in the acetyl group \[[@B12-molecules-21-00672]\]. The resonances of H-3, 4, 5, and 6 appeared in the range of 3.5--4.0 ppm \[[@B12-molecules-21-00672]\]. The FT-IR spectra shown in [Figure 2](#molecules-21-00672-f002){ref-type="fig"} also confirmed the successful introduction of GTMAC into the amino group of chitosan. Bands at around 3268, 2882, 1730, 1646, 1580, 1413, 1320, and 1413 cm^−1^ represent N-H, C-H, carbonyl group, primary amide, secondary amide, C-H of secondary amide, and C-N stretching, respectively, which are general characteristic vibrations of GlcN and GlcNAc. A new band at 1475 cm^−1^ in the HTCC spectrum indicates the introduction of trimethylammonium group on the chitosan backbone \[[@B13-molecules-21-00672]\].

Zeta-potential profiles of chitosan and HTCC as a function of pH are shown in [Figure 3](#molecules-21-00672-f003){ref-type="fig"}. HTCC showed a highly positive zeta-potential value of +50.98 mV at pH 2. Chitosan also revealed a similar value to HTCC because the amino groups in the chitosan molecules are fully protonated at low pH. However, the zeta-potential value of chitosan decreased below zero at increasing pH. The zeta-potential value of HTCC also decreased with increasing pH; however, this change was more gradual and retained a positive value over the whole pH range. From these results, we concluded that chitosan could be successfully modified with GTMAC to provide permanent positive value, regardless of changes in pH.

2.2. Appearance and Encapsulation Efficiency of Nanostructured Lipid Carriers {#sec2dot2-molecules-21-00672}
-----------------------------------------------------------------------------

Different formulations of NLC dispersion were prepared using a hot emulsification method based on phase inversion technique, with the aid of ultrasonic treatment. Compositions of lipid and aqueous phases are represented in [Table 1](#molecules-21-00672-t001){ref-type="table"}. Blank LNC, indomethacin-loaded NLC, chitosan-coated NLC, and HTCC-coated NLC formulations were abbreviated to NLC_B, NLC_I, NLC/CS_I, and NLC/HTCC_I, respectively. NLC_B formulation was translucent and whitish in appearance. NLC_I formulation was translucent and yellowish, while the NLC/CS_I and NLC/HTCC_I formulations were yellowish, turbid, and milky after preparation. All indomethacin-loaded formulations had a yellowish tinge because indomethacin particle (white) turns bright yellow upon dissolution in lipid phase. After storage for a month, visual observation indicated particle aggregation and precipitation with growing turbidity in NLC_B and NLC_I formulations. In agreement with previous reports that suggested that macromolecular biopolymers stabilize lipid colloids upon storage, chitosan and HTCC seemed to stabilize the surface of the lipid particle to become resistant to inter-particle aggregation \[[@B14-molecules-21-00672]\].

The encapsulation efficiency of three different formulations of indomethacin-loaded NLC was evaluated and the results are represented in [Table 1](#molecules-21-00672-t001){ref-type="table"}. Encapsulation efficiency of NLC_I formulation was low, despite the high solubility of indomethacin in lipid phase. On the other hand, more drugs were incorporated in NLC/CS_I and NLC/HTCC_I formulations than in the NLC_I formulation. It is assumed that some of the drug molecules would exist at the lipid surface or surfactant layer, so that, the surface-bound drug fraction could easily diffuse out upon dilution and storage. However, for the NLC/CS_I and NLC/HTCC_I formulations, surface coverage with the coating material could prevent the diffusion of surface-bound drug molecules.

2.3. Particle Size Distribution and Zeta-Potential Profiles {#sec2dot3-molecules-21-00672}
-----------------------------------------------------------

Mean particle sizes and polydispersity indexes (PDI) of NLC/CS and NLC/HTCC formulations are listed in [Table 2](#molecules-21-00672-t002){ref-type="table"}. The mean particle size increased significantly with the addition of chitosan and HTCC, while the PDI value decreased. An increase in mean particle size of NLC/CS and NLC/HTCC formulations seems to relate to their viscosity of the continuous phase. Prior to the preparation of NLC formulation, viscosity values of chitosan and HTCC solutions were 4.8 and 4.2 mPa·s at 80 °C, respectively, which were approximate 4 times higher than that of deionized water. The viscosity of NLC/CS and NLC/HTCC formulations increased after phase inversion. Subsequent ultrasonic treatment increased the viscosities of NLC/CS_I and NLC/HTCC_I formulations up to 87 and 82 mPa·s, respectively. In cases of NLC_B and NLC_I formulations, viscosity increased up to 3.9 and 4.8 mPa·s, respectively, after ultrasonic treatment.

An increase in viscosity of the continuous phase inhibits the mobility and flexibility of surfactant molecules, which retards the adsorption of the surfactant on the surface of newly formed lipid particles. An increase in viscosity of aqueous medium also makes it harder to achieve sufficient acoustic cavitation, which is a powerful driving force for particle reduction during ultrasonic treatment.

The zeta-potential profiles of the NLC formulations as a function of pH are shown in [Figure 4](#molecules-21-00672-f004){ref-type="fig"}. The formulations of NLC_B and NLC_I showed almost zero mV at pH 2 and 4, which gradually decreased to negative value with increasing pH. The carboxyl groups of oleic acid chains are responsible for the zeta-potentials of NLC_B and NLC_I formulations because carboxyl groups are protonated at low pH and deprotonated at high pH to give a negative zeta-potential value. On the other hand, the formulations of NLC/CS_I and NLC/HTCC_I showed a highly positive zeta-potential value at low pH owing to protonation of the amino group of chitosan and the quaternized ammonium group of HTCC. The zeta-potential values of NLC/CS_I and NLC/HTCC_I also decreased with increasing pH owing to deprotonation of the carboxyl group of oleic acid chain, but more gradually than those of NLC_B and NLC_I formulations.

2.4. Differential Scanning Calorimetry {#sec2dot4-molecules-21-00672}
--------------------------------------

Melting behavior and relative crystallinity of NLC formulations were compared with the bulk lipid material as shown in [Table 3](#molecules-21-00672-t003){ref-type="table"}. Melting peaks of glyceryl monostearate component for bulk lipid, NLC/HTCC_I, and the other formulations were observed at 58.4, 52.5, and around 47 °C, respectively. As crystallinity of NLC formulations increased, melting point increased as well. It is known that higher crystallinity (highly ordered lipid structure) affects negatively the performance of lipid based carriers such as less encapsulation efficiency and initial burst release *in vitro* \[[@B15-molecules-21-00672]\]. However, in this study, interestingly NLC/HTCC_I formulation showed relatively high crystallinity compared to the other formulations, which seems not to affect the encapsulation efficiency and *in vitro* drug release. Although NLC/HTCC_I formulation was higher in crystallinity, it still provides enough space for entrapment of guest molecules. In addition, higher encapsulation efficiency and less initial drug burst were observed in NLC/HTCC_I formulation compared to the other formulations during *in vitro* test.

Endothermic curves of bulk lipid, indomethacin, and their mixture are shown in [Figure 5](#molecules-21-00672-f005){ref-type="fig"}a. Melting peaks of bulk lipid and indomethacin appeared at 58.4 and 162.7 °C, respectively. The mixture of lipid phase and indomethacin showed relatively low melting point and low enthalpy compared to individual lipid or indomethacin since melting and subsequent cooling induced the recrystallization between lipid and indomethacin resulting in the change in the crystalline state \[[@B16-molecules-21-00672]\]. Melting peaks of NLC formulations are shown in [Figure 5](#molecules-21-00672-f005){ref-type="fig"}b. The melting points and enthalpy values were relatively low compared to bulk lipid owing to the same reason in the mixture. Melting peak did not appear in NLC/HTCC_I formulation, but tiny peaks were observed in NLC_I (116.9 °C) and NLC/CS_I (114.4 °C) formulations.

2.5. In vitro Drug Release {#sec2dot5-molecules-21-00672}
--------------------------

[Figure 6](#molecules-21-00672-f006){ref-type="fig"} shows *in vitro* release profiles of three different indomethacin loaded NLC formulations. The release rate of indomethacin from three different NLC formulations varied depending on the formulations for the carriers. For the all formulations tested in the PBS buffer, indomethacin released fast at the initial period of the *in vitro* release test but subsequently released slowly over time. The order of drug release rate in the formulations was found to decrease in the following order NLC_I \> NLC/CS_I \> NLC/HTCC_I \> drug for 32 h. NLC formulations coated with chitosan and HTCC showed intermediate drug release rate; the cationic surface modification of lipid carrier using chitosan and HTCC provided sustained release characteristics for the indomethacin loaded lipid carriers. It is expected that chitosan and HTCC coated lipid carrier could enhance dissolution rate of drug thanks to the sustained release behavior. In addition, the mucoadhesive property of chitosan and HTCC contributes to the increase in bioavailability of drug since residence time was prolonged in the gastrointestinal track.

*In vitro* release profiles of indomethacin loaded NLC formulations were fitted using various non-linear regression models such as zero order, first order, Higuchi, and Korsmeyer-Peppas equations as shown in [Figure 6](#molecules-21-00672-f006){ref-type="fig"}. In addition, the regression coefficient (R^2^) and release exponent (n) values calculated using the non-linear regression models for the formulations are listed in [Table 4](#molecules-21-00672-t004){ref-type="table"}. All NLC formulations were fitted well with Korsmeyer-Peppas model since R^2^ values of NLC_I, NLC/CS_I and NLC/HTCC_I were 0.955, 0.9372, and 0.9645, respectively. The n value (\<0.43) of Korsmeyer-Peppas equation indicated that the release behavior of all formulations followed Fickian diffusion mechanism.

2.6. Static In vitro Digestion {#sec2dot6-molecules-21-00672}
------------------------------

*In vitro* drug release characteristics of indomethacin with the presence of digestive enzymes were measured in static, simulated gastric and intestinal fluids for 4 h (2 h each), and the results are shown in [Figure 7](#molecules-21-00672-f007){ref-type="fig"}. For NLC_I and NLC/CS_I formulations, release rates of indomethacin from lipid particles were relatively fast in the simulated gastric fluid and slow in the intestinal fluid. We also observed that more than 60% of entrapped indomethacin was released from lipid nanoparticles in the gastric fluid. NLC/HTCC_I formulation showed a relatively slow release rate of indomethacin (approximately 30% within 2 h), and similar release characteristics to the other formulations in the simulated intestinal fluid. From the theoretical point of view, rapid release of drug entrapped in lipid nanoparticle should take place in the intestinal fluid in which lipolysis occurs. In this study, however, significant amounts of indomethacin were released in the gastric fluid. Thus, we assumed that a significant amount of indomethacin was distributed on the surface of the lipid particle or the interface between hydrophobic region of lipid and the surfactant layer during crystallization of the lipid particle. This surface-bound indomethacin could simply diffuse out into aqueous medium during digestion. For NLC/HTCC_I formulation, HTCC with positively charged alkyl chains on the surface of the lipid particle seemed to prevent the diffusion of indomethacin molecules, thus retarding the release of the drug in the gastric fluid.

3. Experimental Section {#sec3-molecules-21-00672}
=======================

3.1. Synthesis and Characterization of HTCC {#sec3dot1-molecules-21-00672}
-------------------------------------------

Chitosan (Mw 600,000--800,000, DD 90%) and glycidyl trimethylammonium chloride (GTMAC) were purchased from Sigma-Aldrich (St. Louis, MO, USA) and used to synthesize HTCC. *N*-(2-Hydroxy)propyl-3-trimethyl ammonium chitosan chloride (HTCC) was prepared by reacting chitosan with GTMAC in acetic aqueous solution (2% *v*/*v*) \[[@B17-molecules-21-00672]\]. Chitosan powder (6 g) was dissolved in 500 mL of acetic aqueous solution under magnetic stirring at 60 °C. Following complete dissolution of chitosan particles, the temperature was raised to 85 °C with constant stirring. GTMAC was added to the chitosan solution dropwise in five portions at 3-h intervals (7.3 mL each). The total reaction time was 18 h from the first addition of GTMAC. The reaction mixture was then cooled to room temperature and diluted with ethanol. HTCC was precipitated by pouring the reaction mixture in acetone. The precipitate was isolated by centrifugation and washed by ethanol, acetone and finally, diethyl ether. The final product was dried and kept in a desiccator until use.

FT-IR spectra were recorded on a Nicolet 380 FT-IR Spectrometer (Thermo Fisher Scientific Inc., Waltham, MA, USA). ^1^H-NMR spectra were obtained using a Bruker Avance II 500 spectrophotometer (Karlsruhe, Germany) at room temperature. The data was collected with 128 scans. NMR samples were prepared by dissolving chitosan and HTCC powder in D~2~O containing a drop of DCl. Zeta potentials were measured using a zeta-potential analyzer (Delsa nano C, Beckman Coulter, Inc., Fullerton, CA, USA) at a pH range of 2--10.

3.2. Solubility Test of Indomethacin in Lipid Phase {#sec3dot2-molecules-21-00672}
---------------------------------------------------

Liquid oleic acid and solid glyceryl monostearate were used as components of lipid matrix and Tween 80 was used as a surfactant. They were purchased from Sigma-Aldrich. Indomethacin was used as a model drug and purchased from Sigma-Aldrich. Chitosan and HTCC prepared as described above, were used for surface modification of lipid nanoparticles.

The solubility of indomethacin in lipid phase consisting of oleic acid, glyceryl monostearate, and Tween 80 (1:1:1, *w*/*w*/*w*) was determined prior to encapsulation. Indomethacin (100 mg) was dissolved in 1 g of lipid phase at 80 °C for 20 min and cooled to room temperature. The lipid phase was centrifuged at 8000 rpm for 2 min at 40 °C to remove undissolved drug particles. The supernatant was separated carefully from the sediment and dissolved in DMSO at 60 °C. After cooling, the solution was centrifuged at 8000 rpm for 30 min at 4 °C to separate the oil phase. The DMSO layer was carefully transferred to a cuvette and the absorbance was measured at a wavelength of 320 nm on a spectrophotometer (DU 730, Beckman Coulter, Inc., Fullerton, CA, USA). A calibration curve was prepared from the indomethacin standard solutions (3, 5, 10, 20, 30, 40, 50 μg/mL in DMSO). The concentration of indomethacin in the lipid phase was calculated from calibration curve (R^2^ = 0.9993).

3.3. Preparation of Nanostructured Lipid Carriers {#sec3dot3-molecules-21-00672}
-------------------------------------------------

Four different formulations of nanostructured lipid carrier were prepared by a two-step emulsification method. In the first step, coarse emulsion was prepared by phase inversion emulsification. Lipid phase (3%) and 48.5 mL of aqueous phase were heated to 80 °C separately, and the aqueous phase was added dropwise to the lipid phase at a constant rate (5 mL/min) using a peristaltic pump (Longer Precision Pump Co. Ltd., Hebei, China) under magnetic stirring. For NLC/CS_I and NLC/HTCC_I formulations, 0.1% chitosan and HTCC were dissolved directly in the aqueous phase. The coarse emulsion was further stirred for 10 min. In the second step, the coarse emulsion was treated with a probe ultrasonic processor (VCX 750, Sonics & Materials, Inc., Newtown, CT, USA) at 35% amplitude for 20 min. The hot nanoemulsion was cooled to room temperature in order to induce crystallization.

3.4. Particle Size Measurement {#sec3dot4-molecules-21-00672}
------------------------------

Hydrodynamic particle diameters were measured using a particle size analyzer (Delsa nano C, Beckman Coulter, Inc.). Mean particle size and polydispersity index were recorded based on intensity-based distribution. Each sample was measured in triplicate with three different sets at 25 °C and a scattering angle of 165°.

3.5. Zeta-Potential Measurement {#sec3dot5-molecules-21-00672}
-------------------------------

Zeta-potential was measured to determine surface charge distributions as a function of pH. Prior to measurement, 10 mL of LNC dispersions was washed with ethanol and water three times by repeated centrifugation and resuspension. The final precipitates were redispersed in 10 mL of deionized water by ultrasonic treatment at 30% amplitude for 10 min. Each sample was diluted in deionized water and subjected to a pH gradient from 2 to 10. Then, the diluted sample was injected into a flow cell and the zeta-potential was measured at different cell positions, as follows: 0.7, 0.35, 0, −0.35 and −0.7. Each sample was measured in triplicate with three different sets at 25 °C and a scattering angle of 35° using a zeta-potential analyzer.

3.6. Encapsulation Efficiency {#sec3dot6-molecules-21-00672}
-----------------------------

Encapsulation efficiency and drug loading were determined by measuring the concentration of indomethacin loaded in the lipid carrier. A 1 mL aliquot of NLC dispersion was added to 4 mL of DMSO and stirred at 60 °C in order to completely dissolve the lipid particle and collect the released indomethacin. The mixture was then cooled and filtered through a 0.2 μm syringe filter. An HPLC system (Agilent Technologies, Santa Clara, CA, USA) equipped with an auto sampler and U*V*/*V*is detector was used to determine the concentration of indomethacin. The chromatograms of indomethacin were recorded using a Unisol reversed-phase C18 column (4.6 mm × 250 mm, 5 μm, 100 Å) (Agela Technologies, Wilmington, DE, USA) with a U*V*/*V*is detector at 320 nm. The flow rate was 1 mL/min and the mobile phase consisted of acetonitrile and 0.02 M acetate buffer (60:40, *v*/*v*). A calibration curve (R^2^ = 0.9998) was prepared from indomethacin standard solutions (10, 50, 100, 300, 500, 700 and 1000 μg/mL). Encapsulation efficiency was calculated using the following equation \[[@B18-molecules-21-00672]\]. $$\text{Encapsulation\ efficiency}\left( \text{\%} \right) = ~\frac{\text{Total\ drug\ content\ enprapped}}{\text{Initial\ drug\ content}}~ \times 100$$

3.7. Differential Scanning Calorimetry {#sec3dot7-molecules-21-00672}
--------------------------------------

Melting behaviors and relative crystallinity of the NLC formulations were determined by differential scanning calorimetry (DSC 200 F3, Netzsch-Gerätebau GmbH, Selb, Germany). For the DSC measurement, exactly 3 mg of the lyophilized NLC formulations were weighed in a standard aluminum pan, and hermetically sealed with a standard aluminum lid. An empty pan was used as a reference. All samples were heated and cooled from 0 to 200 °C at a scan rate of 5 °C/min. Melting temperature and relative crystallinity of the formulations were determined from the melting curve based on the temperature at which endothermic peak appeared and the integration of the peak, respectively. Crystallinity was calculated by the manufacturer's instructions (Netzsch-Gerätebau GmbH). In this study, crystallization enthalpy of all NLC formulations was negligible. $$\text{Relative\ crystallinity}\left( \text{\%} \right) = ~\frac{\text{Integration\ of\ melting\ enthalpy\ of\ NLC}}{\text{Integration\ of\ melting\ enthalpy\ of\ bulk\ lipid}} \times 100$$

3.8. In vitro Drug Release Test {#sec3dot8-molecules-21-00672}
-------------------------------

*In vitro* release test of indomethacin loaded NLC carriers was carried out for NLC_I, NLC/CS_I and NLC/HTCC_I formulations. Briefly, 5 mL of aqueous NLC formulations equivalent to 4.2, 5.3 and 5.6 mg indomethacin for NLC_I, NLC/CS_I and NLC/HTCC_I, respectively, were introduced in 10 mM PBS (pH 7.4, Sigma-Aldrich) solution in 250 mL flask. Additionally, drug release test on non-encapsulated indomethacin (7.4 mg) was performed as a control group. The flasks with 100 mL of *in vitro* release test solutions were incubated at 37 °C on a temperature controlled hot plate with constant stirring at 300 rpm for 36 h. Five mL aliquot was collected from each flask at predetermined time intervals using a syringe with a 0.45 μm pre-filter. After collecting each aliquot, 5 mL of fresh PBS buffer solution was added to the flask. The collected sample solution was filtered using 0.22 μm syringe filter again and transferred to a cuvette. Absorbance was measured at a wavelength of 298 nm using a spectrophotometer. A calibration curve (R^2^ = 0.9966) was plotted using the absorbance data measured at indomethacin concentrations (1, 3, 5, 10, 30, 50, and 100 μg/mL in 10mM NaOH). *In vitro* drug release tests were performed in triplicate for each sample. *In vitro* release profiles were fitted using several non-linear models such as zero-order (cumulative percentage of drug released *vs.* time), first-order (log cumulative percentage of drug remaining *vs.* time), Higuchi (cumulative percentage of released *vs.* square root of time), and Korsmeyer-Peppas (log cumulative percentage of drug released *vs.* log time) equations.

3.9. Static in Vitro Digestion Test {#sec3dot9-molecules-21-00672}
-----------------------------------

The indomethacin release properties of lipid nanoparticles were determined by a static *in vitro* digestion model described by Minekus *et al.* \[[@B17-molecules-21-00672]\]. Digestion was initiated by mixing 10 mL of NLC dispersion with 9 mL of simulated gastric fluid (SGF) containing electrolytes and pepsin (EC 3.4.23.1) (6.9 mM KCl, 9.0 mM KH~2~PO~4~, 12.5 mM NaHCO~3~, 11.8 mM NaCl, 0.4 mM MgCl~2~(H~2~O)~6~, 0.5 mM (NH~4~)~2~CO~3~, 0.15 mM CaCl~2~(H~2~O)~2~, 2000 U/mL pepsin). The pH of the mixture was adjusted to 3 by 1N HCl solution, and the resulting mixture was made up to 20 mL using deionized water. The mixture was incubated at 37 °C under constant magnetic stirring at 300 rpm for 2 h. After digestion in SGF, 10 mL of gastric chyme was mixed with 9 mL of simulated intestinal fluid (SIF) containing appropriate electrolyte concentrations, pancreatin (EC 232-468-9,4 USP specifications), and bile extract (bile extract porcine, Sigma-Aldrich) (6.8 mM KCl, 0.8 mM KH~2~PO~4~, 85 mM NaHCO~3~, 38.4 mM NaCl, 0.33 mM MgCl~2~(H~2~O)~6~, 0.6 mM CaCl~2~(H~2~O)~2~, 800 U/mL pancreatin, 300 mg bile extract porcine), and incubated for a further 2 h. During the digestion, 1 mL of reaction mixture was withdrawn and the same volume of fresh SGF or SIF solution was added every 1 h. Free indomethacin molecules were collected by ultrafiltration (Vivaspin20 1000K device, MWCO 1,000 K, Sartorius Stedim Lab Ltd., Gloucestershire, UK). The amount of free indomethacin concentration was measured by HPLC described in the previous section.

4. Conclusions {#sec4-molecules-21-00672}
==============

The present research paper proposed cationically modified lipid-based drug carriers (NLCs) for improving water solubility and bioavailability of poorly soluble drug. Indomethacin was selected as a model drug and incorporated in NLCs. Positively charged chitosan derivative, HTCC was synthesized to modify the surface of NLCs cationically. NLC/CS_I and NLC/HTTC_I formulations showed higher encapsulation efficiency for indomethacin than NLC_I formulation. NLC/CS_I and NLC/HTCC_I formulations are considered as effective carriers for sustained drug release. Thus, it is concluded that positively charged NLCs such as NLC/CS_I and NLC/HTCC_I formulations could improve bioavailability of poorly soluble drugs.
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![Zeta-potential profiles of different NLC formulations as a function of pH. NLC_B, blank NLC formulation; NLC_I, indomethacin loaded NLC formulation; NLC/CS_I: indomethacin loaded NLC formulation coated with chitosan; NLC/HTCC_I, indomethacin loaded NLC formulation coated with HTCC.](molecules-21-00672-g004){#molecules-21-00672-f004}

![Endothermic peaks of (**a**) bulk glyceryl monostearate, indomethacin, and their mixture and (**b**) NLC formulations; \*G, endothermic peak of glyceryl monostearate; \*I, endothermic peak of indomethacin.](molecules-21-00672-g005){#molecules-21-00672-f005}

![*In vitro* release profiles of three different indomethacin loaded NLC formulations. NLC_I, indomethacin loaded NLC formulation; NLC/CS_I: indomethacin loaded NLC formulation coated with chitosan; NLC/HTCC_I, indomethacin loaded NLC formulation coated with HTCC. Each formulation was fitted according to Korsmeyer-Peppas regression model except pure indomethacin.](molecules-21-00672-g006){#molecules-21-00672-f006}

![*In vitro* digestion characteristics of three different indomethacin loaded NLC formulations. NLC_I, indomethacin loaded NLC formulation; NLC/CS_I: indomethacin loaded NLC formulation coated with chitosan; NLC/HTCC_I, indomethacin loaded NLC formulation coated with HTCC.](molecules-21-00672-g007){#molecules-21-00672-f007}

molecules-21-00672-t001_Table 1

###### 

Compositions to prepare indomethacin loaded NLC formulations.

  Formulation   Solid Lipid (%)   Liquid Lipid (%)   Tween 80 (%)   Coating Material (%)   Viscosity of Aqueous Phase (mPa·s)   Indomethacin (mg)
  ------------- ----------------- ------------------ -------------- ---------------------- ------------------------------------ -------------------
  NLC_B         1                 1                  1              \-                     0.36                                 \-
  NLC_I         1                 1                  1              \-                     0.36                                 74
  NLC/CS_I      1                 1                  1              0.1                    4.8                                  74
  NLC/HTCC_I    1                 1                  1              0.1                    4.2                                  74

NLC_B, blank NLC formulation; NLC_I, indomethacin loaded NLC formulation; NLC/CS_I, indomethacin loaded NLC formulation coated with chitosan; NLC/HTCC_I, indomethacin loaded NLC formulation coated with HTCC. Viscosity values were measured at 80 °C.

molecules-21-00672-t002_Table 2

###### 

Particle size distribution and encapsulation efficiency of indomethacin loaded NLC formulations.

  Formulation   Particle Size Distribution   Encapsulation Efficiency (%)   Drug Loading (%)   
  ------------- ---------------------------- ------------------------------ ------------------ ----------------
  NLC_B         255.6 ± 2.4 ^b^              0.268 ± 0.002 ^a^              \-                 \-
  NLC_I         277.0 ± 22.9 ^b^             0.270 ± 0.015 ^a^              56.8 ± 0.5 ^c^     4.2 ± 0.04 ^c^
  NLC/CS_I      360.2 ± 34.1 ^a^             0.247 ± 0.026 ^b^              72.2 ± 1.9 ^b^     5.3 ± 0.13 ^b^
  NLC/HTCC_I    351.9 ± 22.4 ^a^             0.238 ± 0.02 ^b^               74.4 ± 0.7 ^a^     5.5 ± 0.05 ^a^

NLC_B, blank NLC formulation; NLC_I, indomethacin loaded NLC formulation; NLC/CS_I, indomethacin loaded NLC formulation coated with chitosan; NLC/HTCC_I, indomethacin loaded NLC formulation coated with HTCC. Letters in the same column indicates significant difference at *p* \< 0.05.
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###### 

Melting parameters and relative crystallinity of indomethacin loaded NLC formulations.

  Formulation   Melting Temp. (°C)   Enthalpy (J/mg)   Relative Crystallinity (%)
  ------------- -------------------- ----------------- ----------------------------
  NLC_B         47.4 ± 0.9 ^b^       31.9 ± 1.6 ^b^    30.0 ± 069 ^b^
  NLC_I         46.8 ± 0.5 ^b^       31.8 ± 4.3 ^b^    30.0 ± 0.0 ^b^
  NLC/CS_I      47.8 ± 2.1 ^b^       31.0 ± 2.3 ^b^    29.2 ± 2.1 ^b^
  NLC/HTCC_I    52.4 ± 0.5 ^a^       39.0 ± 0.5 ^a^    36.7 ± 0.4 ^a^

NLC_B, blank NLC formulation; NLC_I, indomethacin loaded NLC formulation; NLC/CS_I, indomethacin loaded NLC formulation coated with chitosan; NLC/HTCC_I, indomethacin loaded NLC formulation coated with HTCC. Different letters in the same column indicate a significant difference (*p* \< 0.05).
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###### 

Regression coefficient (R^2^) and release exponent (n) values calculated using the non-linear regression models for *in vitro* release profiles of indomethacin loaded NLC formulations.

  Formulation   Zero Order R^2^   First Order R^2^   Higuchi R^2^   Korsmeyer-Peppas R^2^ (*n*)
  ------------- ----------------- ------------------ -------------- -----------------------------
  NLC_I         0.7319            0.8545             0.8822         0.9555 (0.2202)
  NLC/CS_I      0.7405            0.8126             0.8894         0.9372 (0.3312)
  NLC/HTCC_I    0.7894            0.8263             0.9172         0.9645 (0.2200)

NLC_B, blank NLC formulation; NLC_I, indomethacin loaded NLC formulation; NLC/CS_I, indomethacin loaded NLC formulation coated with chitosan; NLC/HTCC_I, indomethacin loaded NLC formulation coated with HTCC. *n* value indicates release exponent.
